Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced that the first subject has been dosed in the Phase 2 clinical study of CVN424 in individuals with early-stage Parkinson’s disease.

研究评估CVN424作为早期帕金森氏病单一疗法的疗效和安全性-波士顿，2023年11月13日（GLOBE NEWSWIRE）-Cerevance，一家专注于开发用于中枢神经系统（CNS）疾病的新型精确疗法的公司，今天宣布，第一个受试者已在CVN424的早期帕金森氏病患者的2期临床研究中给药。

The ASCEND (A novel Selective Compound to ENable Individuals with Parkinson’s Disease) study will explore the potential use of CVN424 as a novel and innovative treatment option for individuals with early-stage Parkinson’s disease. 'We are delighted to announce the commencement of our ASCEND study in individuals who have recently been diagnosed with Parkinson's disease and not yet received levodopa treatment,' stated Craig Thompson, chief executive officer of Cerevance.

ASCEND（一种使帕金森病患者成为可能的新型选择性化合物）研究将探索CVN424作为早期帕金森病患者新型创新治疗选择的潜在用途Cerevance首席执行官Craig Thompson说，我们很高兴宣布ASCEND研究开始于最近被诊断患有帕金森病但尚未接受左旋多巴治疗的个体。

'This study aims to build upon the promising results from our previous Phase 2 trial of CVN424 as an adjunctive therapy for later-stage Parkinson's disease. Our objective is to demonstrate the advantages of CVN424 over existing treatments in improving both the motor and non-motor symptoms of Parkinson's disease.

'这项研究的目的是建立在我们之前的CVN424 2期临床试验作为晚期帕金森病辅助治疗的有希望的结果的基础上。我们的目标是证明CVN424优于现有治疗方法在改善帕金森病的运动和非运动症状方面的优势。

With ASCEND, we take a significant step closer to providing patients with an innovative, safe, and well-tolerated treatment that addresses multiple facets of this disease.' The Phase 2 ASCEND study is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of CVN424 in individuals with early, untreated Parkinson’s disease.

随着ASCEND的发展，我们更接近为患者提供创新，安全且耐受性良好的治疗方法，以解决该疾病的多个方面2期ASCEND研究是一项随机，双盲，安慰剂对照研究，旨在评估CVN424在早期未经治疗的帕金森病患者中的疗效和安全性。

Sixty individuals aged 30 years and older will be randomized to receive a once daily dose of either CVN424 150 mg or placebo. The primary endpoint of the study is CVN424’s ability to improve Parkinson’s disease motor symptoms and the impact .

60名年龄在30岁及以上的人将被随机分配接受每日一次剂量的CVN424 150 mg或安慰剂。该研究的主要终点是CVN424改善帕金森病运动症状和影响的能力。